The Cyprus presidency’s announcement on 12 May 2026 that Council and Parliament negotiators had reached a provisional agreement on the Critical Medicines Act ended what had been one of the more technically demanding files of the legislative cycle. The text addresses a deceptively narrow problem — recurring shortages of medicines such as antibiotics, insulin, paediatric formulations and certain painkillers — by reshaping the regulatory tools available to the Commission, the European Medicines Agency and national procurement authorities. The political stakes are considerably broader than the file’s modest length suggests.
At the centre of the agreement is a new obligation for contracting authorities to apply resilience-related requirements in public procurement procedures for critical medicines. In practice, this means hospitals and national health services will be required to weight criteria such as supply-chain diversification, geographic origin of active pharmaceutical ingredients, and manufacturer stock-holding commitments when awarding contracts. Lowest-price awards, which have dominated European generic procurement for two decades and have been widely blamed for driving production to a small number of Asian suppliers, will no longer survive without explicit justification.
The compromise text reduced from nine to five the threshold of Member States required to submit a request asking the Commission to procure jointly on their behalf. The change is significant. Joint procurement has been one of the most underused powers in the EU health toolkit, partly because the original numerical hurdle made coalition-building cumbersome. Lowering it to five capitals creates a realistic pathway for smaller Member States to pool purchasing power for products where unit volumes alone would otherwise leave them at the mercy of single suppliers. EMA’s welcome of the agreement, issued the same week, emphasised the operational role the agency will play in identifying which products qualify for joint action.
The Act also introduces incentives for EU-based manufacturing of critical medicines and their active ingredients. These include financial support mechanisms layered onto existing Horizon Europe and IPCEI structures, accelerated regulatory pathways for capacity expansions, and the possibility of designating strategic projects of EU interest with shortened permitting timelines. The aim, as several MEPs from the Renew group framed it after the trilogue, is pharmaceutical sovereignty — a phrase that has migrated from defence and digital policy into a domain where dependence on third countries has accumulated quietly over decades.
What the Critical Medicines Act deliberately does not do is also instructive. It does not impose mandatory minimum stock-holding obligations on manufacturers, an idea pushed by several parliamentarians but resisted by the Council on cost-allocation grounds. It does not create a new EU agency, with delivery instead distributed across HERA, the European Medicines Agency and national competent authorities. And it does not duplicate the broader EU pharmaceutical package, the political agreement on which was reached in December 2025 and whose adopted acts are expected to enter into force later this year, opening a transition period running through 2028.
The political timing of the Act matters. With several Member States still working through chronic shortages of antibiotics and oncology medicines reported by national pharmacy associations through the winter, ministers and MEPs have been under sustained pressure to demonstrate that the European Health Union, formally completed in October 2022, can deliver beyond crisis-response architecture. The Critical Medicines Act, paired with the wider pharmaceutical package and the existing HERA mandate running through 2027, gives the Commission its most coherent toolkit yet for what it now openly calls a strategic industry. Implementation will be the harder test.
